All In Biotech

Drug Trial Radar · NCT06491563

Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

A Phase 2 Multicenter, Open-label Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and Pegylated Interferon Alpha (PEG-IFNα) for the Treatment of Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

150

Actual

Start

Aug 6, 2024

Primary completion

Aug 5, 2026

Study completion Aug 5, 2026

Sponsor

Lead sponsor
Brii Biosciences LimitedIndustry
Sponsor type
Industry
Collaborators
Vir Biotechnology, Inc.
First posted
Jul 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.

Conditions

  • For Treatment of Chronic Hepatitis B Virus Infection

Interventions

  • BRII-179Biological

    BRII-179 will be given via intramuscular injection

  • BRII-835 (VIR-2218)Drug

    BRII-835 will be given via subcutaneous injection

  • PEG-IFNαBiological

    PEG-IFNα will be given via subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants achieving HBsAg seroclearance at 24 weeks post end of study treatment in anti-HBs responders compared with non-responders defined at protocol-specific timepointTime frame: 24 weeks post end of treatment

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Investigative Site 86004

    Beijing, Beijing Municipality, China

  • Investigative Site 86009

    Beijing, Beijing Municipality, China

  • Investigative Site 86015

    Xiamen, Fujian, China

  • Investigative Site 86012

    Foshan, Guangdong, China

  • Investigative Site 86001

    Guangzhou, Guangdong, China

  • Investigative Site 86013

    Guangzhou, Guangdong, China

  • Investigative Site 86002

    Shenzhen, Guangdong, China

  • Investigative Site 86003

    Shanghai, Shanghai Municipality, China

  • Investigative Site 86008

    Shanghai, Shanghai Municipality, China

  • Investigative Site 86007

    Chengdu, Sichuan, China

  • Investigative Site 86011

    Chengdu, Sichuan, China

  • Investigative Site 86005

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.